Список литературы

Поставить закладку

Волгина Г.В., Фролова Н.Ф. Бессимптомная бактериурия у беременных: эволюция общепринятых взглядов // Терапия.– 2020.–1(35).–С. 104-111. DOI: 10.18565/therapy.2020.1.104-111.
Демидко Ю.Л. Изменения в федеральных клинических рекомендациях-2020. - Урология сегодня. – 2020.- №4 (62). - URL: https://ru.calameo.com/read/00452073637004b2b55b3
Зайцев А.В. , Ширяев А.А. , Ким Ю.А. , и др. Инфекции мочевыводящих путей. Современная тактика врача-уролога// РМЖ.– 2019.– 1.–С. 21-26.
Палагин И. С., Сухорукова М. В., Дехнич А. В., и др. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018» // Клин. микробиол. антимикроб. химиотер. – 2019. – 21(2).– С. 134–46. DOI: 10.36488/cmac.2019.2.134-146.
Острый пиелонефрит. Клинические рекомендации – 2019 / Российское общество урологов https://bsmp-kursk.ru/assets/files/local-protocols/Urology/kr-ostryj-pielonefrit.pdf
Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А., Палагин И.С. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. Издательский дом «Уромедиа». М., 2020. 110 с.
Применение нитрофуранов при инфекции мочевых путей. - URL: https://www.umedp.ru/articles/primenenie_nitrofuranov_pri_infektsii_mochevykh_putey.html (accessed: 20.07.2021).
Рафальский В.В., Моисеева Е.М. Эпидемиология неосложнённых внебольничных инфекций мочевыводящих путей в Российской Федерации// Вестник урологии. – 2018.– №2.–C.30–37. DOI 10.21886/2308-6424-2018-6-2-30-37.
Рязанцев В.Е., Власов В.В., Румянцев Ф.В., Киушкин В.О. Динамика антибиотикорезистентности у больных урологического профиля // Эффективная фармакотерапия. – 2020.- Т. 16. № 3.- С. 8–13. [Ryazantsev VE, Vlasov VV, Rumyantsev FV, Kiushkin VO. Dinamika antibiotikorezistentnosti u bol'nykh urologicheskogo profilya [Dynamics of antibiotic resistance in urological patients]. Effektivnaya farmakoterapiya [Effective pharmacotherapy]. 2020; 16 (3): 8–13.(in Russ.)]. DOI 10.33978/2307-3586-2020- 16-3-8-13.
Стратегия предупреждения распространения антимикробной резистентности в Российской Федерации на период до 2030 года [Электронный ресурс]: утв. распоряжением Правительства Российской Федерации от 25 сент. 2017 г. № 2045-р // ГАРАНТ.РУ. Инф.-правовой портал.
Сурсякова К.И., Сафьянова Т.В. Некоторые эпидемиологические аспекты инфекций мочевыводящих путей у пациентов госпиталя для ветеранов войн // Эпидемиология и вакцинопрофилактика. – 2019.– 18(1).–С. 105–111.
Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013; 190: 1981-1989. doi: 10.1016/j.juro.2013.04.142.
Bonkat G, Wagenlehner F. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Eur Urol (2018) ), https://doi.org/10.1016/j.eururo.2018.10.057
Bonkat G, Pickard R, Bartoletti R, Cai T, Bruyère F, Geerlings SE, Köves B, Wagenlehner F, Pilatz A, Pradere B, Veeratterapillay R. European Association of Urology. EAU Guidelines urological infections; update 2019. Available from: URL: https://uroweb.org/wpcontent/uploads/EAU-Guidelines-on-Urological-infections-2019.pdf
Droupy S. The therapeutic approach to different forms of cystitis: impact on public health. Urologia. 2017 Sep 14; 84 (Suppl 1): 8 – 15. doi: 10.5301/uj.5000262.
European Medicines Agency. Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use. EMA/668915/2018.Available from: URL: www.ema.europa.eu
European Medicines Agency. Disabling and potentially permanent side effects lead tosuspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA/175398/2019. — Available from: URL: https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolonecontaining-medicinal-products.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5): 269 - 284. doi: 10.1038/nrmicro3432.
Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.doi: 10.1016/j.idc.2013.09.003.
Glover M., Moreira C.G., Sperandio V., Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014;25(1):1–8. doi: 10.1016/j.urols.2013.11.007.
Guglietta A. Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol. 2017 Mar; 12: 239 - 246. doi: 10.2217/fmb-2016-0145.
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.
Kabbani S, Hersh AL, Shapiro DJ, Fleming-Dutra KE, Pavia AT, Hicks LA. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis. 2018;67(1):134–6. DOI: 10.1093/cid/ciy035
Kurt G. Naber. Efficacy and safety of the phytotherapeutic drug Canephron ®N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5: 39 – 46. doi: 10.2147/RRU.S39288.
Lee DS, Lee SJ, Choe HS. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int. 2018:7656752. doi: 10.1155/2018/7656752.
McLellan LK, Hunstad DA. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol Med. 2016 Nov; 22(11): 946 - 957. doi: 10.1016/j.molmed.2016.09.003.
Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, et all. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10): e83–e110. doi: 10.1093/cid/ciy1121.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et all. Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. EAU.2013; Vol.64(1): 118-140. doi: 10.1016/j.eururo.2013.03.004.
Patwardhan V, Kumar D, Goel V, Singh S. Changing prevalence and antibiotic drug resistance pattern of pathogens seen in community-acquired pediatric urinary tract infections at a tertiary care hospital of North India. J Lab Physicians. 2017; Vol. 9. № 4: 264–268. doi: 10.4103/JLP.JLP_149_16.
Porreca A, D'Agostino D, Romagnoli D, Del Giudice F, Maggi M, et al. The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review of Randomized Control Trials. Urologia Internationalis. 2021; 105(7): 531-540. doi: 10.1159/000512582.
Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging health. 2013; 9(5):10.2217/ahe.13.38. doi: 10.2217/ahe.13.38.
Shang YJ, Wang QQ, Zhang JR, Xu YL, Zhang WW, Chen Y, Gu ML, Hu ZD, Deng AM. Systematic review and meta-analysis of flow cytometry in urinary tract infection screening. Clin Chim Acta .2013; 424: 90 - 95. doi: 10.1016/j.cca.2013.05.014.
Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. In press. https://doi.org/10.1016/j.ijantimicag. 2018.04.014
Vervoort J, Xavier BB, Stewardson A, Coenen S, Godycki-Cwirko M, Adriaenssens N, Kowalczyk A, Lammens C, Harbarth S, Goossens H, Malhotra-Kumar S. Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota. J Antimicrob Chemother. 2015 Jul;70(7):1989-92. doi: 10.1093/jac/dkv062.
Wagenlehner FM, Abramov-Sommariva D, Holler M, Steindl H, Naber KG. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double Blind, Parallel-Group, randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327-336. doi: 10.1159/000493368.
World Health Organisation. Global action plan on antimicrobial resistance. Geneva: WHO; 2015. Available from: URL: https://www.who.int/publications/i/item/9789241509763
Wu YR, Rego LL, Christie AL, Lavelle RS, Alhalabi F, Zimmern PE. Recurrent Urinary Tract Infections Due to Bacterial Persistence or Reinfection in Women-Does This Factor Impact Upper Tract Imaging Findings? J Urol. 2016;196:422–428. DOI: 10.1016/j.juro.2016.01.111